Molecular structure of Aurora Kinase Inhibitor II, CAS Number: 331770-21-9
Aurora Kinase Inhibitor II (CAS 331770-21-9)
Alternate Names:
4-(4′-Benzamidoanilino)-6,7-dimethoxyquinazoline
Application:
Aurora Kinase Inhibitor II is a potent and selective ARK inhibitor
CAS Number:
331770-21-9
Purity:
≥90%
Molecular Weight:
400.4
Molecular Formula:
C23H20N4O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Aurora kinase inhibitor II is an anilinoquinazoline that is both a potent and selective ATP-competitive inhibitor of ARK/aurora kinase (IC50 = 310 nM and 240 nM for ARK-1/Aurora A and ARK-2/B, respectively, 1.25 muM in MCF7 cells). This compound has the ability to permeate the cell and is involved in the regulation of the cell cycle, particularly cell division. It is used in research to study the role of Aurora kinase in cell division and to investigate the effects of Aurora kinase inhibition on cell cycle progression.
Aurora Kinase Inhibitor II (CAS 331770-21-9) References
- Progress in the development of selective inhibitors of aurora kinases. | Mortlock, AA., et al. 2005. Curr Top Med Chem. 5: 807-21. PMID: 16101420
- SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. | Heron, NM., et al. 2006. Bioorg Med Chem Lett. 16: 1320-3. PMID: 16337122
- Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation. | Sankaran, S., et al. 2007. Cancer Res. 67: 11186-94. PMID: 18056443
- Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. | Dai, Y., et al. 2008. Blood. 112: 793-804. PMID: 18505786
- Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells. | Sumi, K., et al. 2011. FEBS Lett. 585: 1884-90. PMID: 21557940
- Identification of Ski as a target for Aurora A kinase. | Mosquera, J., et al. 2011. Biochem Biophys Res Commun. 409: 539-43. PMID: 21600873
- Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer. | Male, H., et al. 2012. Lung Cancer. 77: 252-9. PMID: 22498113
- A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | Gao, Y., et al. 2013. Biochem J. 451: 313-28. PMID: 23398362
- RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). | Ezzeldin, M., et al. 2014. Mol Oncol. 8: 1043-53. PMID: 24785097
- Altered expression of Aurora kinases in Arabidopsis results in aneu- and polyploidization. | Demidov, D., et al. 2014. Plant J. 80: 449-61. PMID: 25146886
- Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition. | Sadaie, M., et al. 2015. Mol Biol Cell. 26: 2971-85. PMID: 26133385
- miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression. | Epis, MR., et al. 2017. Oncotarget. 8: 55116-55134. PMID: 28903407
- Identification of a novel anticancer mechanism of Paeoniae Radix extracts based on systematic transcriptome analysis. | Baek, SJ., et al. 2022. Biomed Pharmacother. 148: 112748. PMID: 35219117
Inhibitor of:
ARK-1, and ARK-2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Aurora Kinase Inhibitor II, 1 mg | sc-203827 | 1 mg | $138.00 |